



Baishideng Publishing Group Co., Limited

Flat C, 23/F., Lucky Plaza,
315-321 Lockhart Road,
Wan Chai, Hong Kong, China

ESPS Peer-review Report

Name of Journal: World Journal of Methodology

ESPS Manuscript NO: 7561

Title: NOVEL AGENTS AND FUTURE DIRECTIONS IN MULTIPLE MYELOMA

Reviewer code: 02511796

Science editor: Qi, Yuan

Date sent for review: 2013-11-25 21:30

Date reviewed: 2013-11-29 14:14

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B (Very good)	<input type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)	<input type="checkbox"/> Grade D: rejected	<input type="checkbox"/> Existed	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)		<input type="checkbox"/> No records	<input type="checkbox"/> Major revision

COMMENTS TO AUTHORS

Thank you for the asking me to review the article. It is a comprehensive review. It lacks a little authority as the authors could have gone further to express their views. In this simple trial design may no longer be valid for tumors where new therapies are coming up regularly and choice of these therapies are still experimental. It is also important to be able to detect these tumors early and identify which agents could be beneficial for which client. This aspect could be expanded and this will bring in methodological angles for relevance to this journal. I would suggest: 1) Encourage a revision - look at the scope of this journal and introduce some aspect to meet that. 2) Keep most of the substance on therapies. 3) Future Therapies - Expand here and introduce the novel methodological issues in choosing the right patient and the right way to follow-up to ensure issues such as lead time bias are excluded. Also highlight that with so many agents how we decide on the agents chosen. Are there novel methodological molecular epidemiological methods to select and follow patients. Table - introduce a third column for comments - in this could suggest when this agent will be considered etc. I have enclosed a PDF with some comments. These are general suggestions which the authors has to put together in a workable context.



Baishideng Publishing Group Co., Limited

Flat C, 23/F., Lucky Plaza,
315-321 Lockhart Road,
Wan Chai, Hong Kong, China

ESPS Peer-review Report

Name of Journal: World Journal of Methodology

ESPS Manuscript NO: 7561

Title: NOVEL AGENTS AND FUTURE DIRECTIONS IN MULTIPLE MYELOMA

Reviewer code: 02509357

Science editor: Qi, Yuan

Date sent for review: 2013-11-25 21:30

Date reviewed: 2013-12-15 02:51

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B (Very good)	<input checked="" type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)	<input type="checkbox"/> Grade D: rejected	<input type="checkbox"/> Existed	<input checked="" type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)		<input type="checkbox"/> No records	<input type="checkbox"/> Major revision

COMMENTS TO AUTHORS

This work “Novel agents and future directions in multiple myeloma” is addressing a very important issue of the therapeutic strategies and the drugs for the management of multiple myeloma. However manor points should be considered for improvement. -The first sentence in the page 10 is not completed: “The risk of neurotoxicity early in the disease course represent the major contra.”? -Add references to table 1 -I suggest to add more tables in each section summarizing the contents in simplified way with references -Try to reduce the references list to the most important ones (reference about 28 pages / 55 total)



Baishideng Publishing Group Co., Limited

Flat C, 23/F., Lucky Plaza,
315-321 Lockhart Road,
Wan Chai, Hong Kong, China

ESPS Peer-review Report

Name of Journal: World Journal of Methodology

ESPS Manuscript NO: 7561

Title: NOVEL AGENTS AND FUTURE DIRECTIONS IN MULTIPLE MYELOMA

Reviewer code: 02510582

Science editor: Qi, Yuan

Date sent for review: 2013-11-25 21:30

Date reviewed: 2013-12-17 13:09

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B (Very good)	<input type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)	<input type="checkbox"/> Grade D: rejected	BPG Search:	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)		<input type="checkbox"/> Existed	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

COMMENTS TO AUTHORS

The manuscript written by Roberto Ria et al., is indeed very informative and applicable for wide range of reader, but seriously lack the synchronization. The parts of the manuscript should be rewritten. Specific comments: 1. Include the details up to year 2013 and the trend in figure 1. Also include references as an extra column. 2. Include reference in Table 2 as an extra column. 3. Please include some schematic diagram and the chemical structures of some important compounds. 4. The title "NOVEL AGENTS AND FUTURE DIRECTIONS IN MULTIPLE MYELOMA" is very unclear. Either it should focus on MULTIPLE MYELOMA detection or therapy or some thing else. The title of the manuscript should be changed to clearly address the content of the manuscript. 5. Check grammar of the manuscript.